New Delhi: A suspected fake rabies vaccine operation uncovered in north Delhi has raised fresh concerns about the safety of medicines reaching patients, after laboratory tests found that seized vials failed the required quality standard.
The vaccine involved is Abhayrab, manufactured by Indian Immunologicals Limited through its Human Biologicals Institute division.
The seized vials carried batch number KE25012 and were recovered on April 22 from an unlicensed premises in Mukherjee Nagar during an enforcement operation involving Delhi Police and drug-control officials.
The authorities sent samples from the seized stock to the Central Drugs Laboratory in Kasauli for testing. The laboratory classified the sample as “Not of Standard Quality” and “Misbranded” after it failed the required potency test. The finding prompted the Drugs Controller General of India to alert state drug controllers and ask them to maintain close watch on the identified batch.
The manufacturer has made an important distinction in the case. Indian Immunologicals says the seized vials were not made by the company, even though they carried its product name and the batch number of a genuine Abhayrab batch.
The company compared the seized material with its genuine retained samples and found 17 differences. These reportedly included discrepancies in the packaging artwork, labels, fonts, QR code, cap colour, logo and licence details.
Indian Immunologicals has provided its manufacturing and distribution records to investigators and asked authorities to trace the source of the suspected counterfeit stock.
Four people have been arrested in connection with the case, while investigators continue to examine how the vials were produced and how they reached the unlicensed premises. The regulatory response has also widened, with state drug authorities being asked to watch for the identified batch and take appropriate action.
The concern is particularly serious because this is not an ordinary medicine. Rabies leaves almost no margin for delay once symptoms begin. The disease is almost invariably fatal after clinical symptoms appear, which makes timely and effective post-exposure treatment critical after a suspected exposure.
India continues to face a substantial rabies burden. An ICMR-led national assessment estimated around 5,726 human rabies deaths every year and about 9.1 million animal bites annually. In many of those cases, vaccination forms a crucial part of the treatment given after exposure.
That is why the investigation into the seized Abhayrab vials matters beyond the Delhi premises where they were found. A patient receiving a rabies vaccine has no practical way of judging its potency simply by looking at the vial. The patient relies on hospitals, doctors, pharmacies, distributors, manufacturers and regulators to ensure that the medicine is genuine and has remained within the required storage conditions.
There is also no indication that every Abhayrab vaccine in the market is affected by this case. The investigation centres on the seized vials carrying batch number KE25012, and Indian Immunologicals has said the material recovered by authorities was not its genuine product.
The company has also said genuine Abhayrab supplied through its authorised distribution network remains unaffected. Genuine batches go through quality checks and government batch-release procedures before entering the market.
The seized stock has raised further questions because investigators found differences between the vials and genuine samples. Reports have also pointed to concerns over storage conditions, with the seized material reportedly found outside the 2°C to 8°C temperature range specified for the vaccine. Investigators will have to establish when and how that happened.
For patients and families dealing with an animal bite, however, the immediate priority remains treatment. Medical attention should not be delayed because of the investigation. Rabies vaccination and any additional treatment required after exposure should be taken under medical supervision and obtained through authorised healthcare facilities or licensed pharmacies.
The bigger question now is how far the suspected counterfeit network reached. Investigators will need to establish who produced the vials, where the material came from, who distributed it and whether any other patients may have received doses from the same suspected stock.
Those answers could determine the scale of the case.
For now, the Delhi seizure has exposed a serious weakness that regulators cannot afford to ignore. When a counterfeit medicine carries the identity of a genuine vaccine, the problem is no longer simply about fake packaging or illegal trade.
It reaches directly into the trust patients place in the healthcare system at the moment they are most vulnerable.
